Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).

@article{Valgimigli2014UsefulnessAS,
  title={Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).},
  author={Marco Valgimigli and Pierluigi Tricoci and Zhen Huang and Philip E. G. Aylward and Paul Wayne Armstrong and Frans Van de Werf and Sergio Leonardi and Harvey Douglas White and Petr Widimsk{\'y} and Robert A. Harrington and {\'A}ngel R Cequier and Edmond Chen and Yuliya V Lokhnygina and Lars Wallentin and John T. Strony and Kenneth W. Mahaffey and David J Moliterno},
  journal={The American journal of cardiology},
  year={2014},
  volume={114 5},
  pages={665-73}
}
The therapeutic potential of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (PCI) is unknown. This prespecified analysis of a postrandomization subgroup evaluated the effects of vorapaxar compared with placebo among Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) participants undergoing PCI, focusing on the implanted stent type (drug-eluting stent [DES] vs bare-metal stent… CONTINUE READING